OGT’s NGS panels to be featured in user workshop at AMP 2020

Monday 9 November 2020
Applications:
Product types:
,
Scientist_looking_at_slide_for_website_large

Oxford, UK – 09 November 2020. Oxford Gene Technology (OGT), A Sysmex Group Company, will be hosting a live workshop at the upcoming Association for Molecular Pathology (AMP) 2020 virtual meeting, in which users will explain how OGT’s SureSeq™ NGS panels can increase throughput and save time and cost in the detection of a wide variety of aberrations. The workshop, Implementing SureSeq Myeloid and CLL Panels for comprehensive genomic profiling of haematological malignancies, will be held on Wednesday 18th November at 4:30 PM EST. To find out more and to register for the workshop, visit www.ogt.com/AMP-2020.

During the workshop, Tracy Tucker, PhD, FCCMG, Cytogeneticist and Molecular Geneticist, Cancer Genetics and Genomics, BC Cancer Agency, and Associate Professor, University of British Columbia, will be talking about transitioning CLL FISH analysis into the molecular biomarker era using OGT’s SureSeq CLL + CNV panel. Her presentation will be followed by Elizabeth McCready, PhD, FCCMG, Head of Molecular Cytogenetics, Hamilton Regional Laboratory Medicine Program, and Associate Professor, McMaster University, who will compare a hybridization-based NGS panel versus single analyte and amplicon-based NGS assays for somatic mutation testing in myeloid malignancies, from her experience with OGT’s SureSeq myPanel Custom Myeloid - 49 gene plus panel.

OGT’s NGS panels offer unparalleled coverage uniformity to detect low-frequency SNVs and indels consistently and with confidence. The SureSeq CLL + CNV panel can detect CNVs ranging from single exons to full chromosome arms and trisomies, which allows the profiling of samples for CNVs in the five most commonly aberrated regions in CLL. By replacing multiple assays with a single NGS panel, the SureSeq CLL + CNV panel can increase throughput and reduce turnaround time. OGT’s SureSeq myPanel Custom Myeloid - 49 gene plus panel offers robust detection of difficult to sequence genes such as CEBPA variants, FLT3-ITDs and KMT2A-PTDs, ensuring comprehensive aberration detection in a highly streamlined workflow. OGT’s customers are able to accurately identify a comprehensive range of variants and CNVs using the company’s complimentary, powerful, and easy-to-use Interpret analysis software.

“The AMP virtual meeting is a great opportunity to showcase the exceptional data quality of our NGS panels, and we’re pleased that Drs Tucker and McCready are able to share their research with delegates”, said OGT’s CEO, John Anson. “OGT is fully committed to the NGS space. We offer robust NGS panels that target the most relevant content and various types of aberrations - including CNV detection - and a complete range of NGS consumables, all backed up by the renowned expertise of our technical specialists. Being part of Sysmex, a large, global IVD company, has opened up a number of exciting possibilities for OGT, and we have many exciting plans for developing and expanding our NGS offering.”

To find out more and to register for the workshop, visit www.ogt.com/AMP-2020

 

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.

T: +44 (0) 1865 856800 ; F: +44 (0) 1865 848684

E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech

 

Editor’s notes

About Oxford Gene Technology

Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitrodiagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.

For more information on the Company, please visit our website at www.ogt.com

CytoSure™, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. Cytocell: Some products may not be available in your region.

 

About Sysmex Corporation

Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 50 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs more than 9,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.

For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.